SEMA4A and multiple sclerosis: Blocking antibodies to Sema4A result in decreased clinical and histopathological severity in the mouse model of multiple sclerosis (MS), experimental autoimmune encephalomyelitis, which is a prototypical Th1-mediated autoimmune disorder (Kumanogoh et al., 2002).